She joined Novartis more than 20 years ago and has led several of the company’s oncology businesses over the last six years, including region head of Novartis Oncology Europe.

The upcoming 12th Annual Clinical Trials in Oncology conference will cover a wide range of topics on clinical research in ...

For Novartis, oncology is a key strategic area, but it is still short of dominating the field. It wants to get ahead of competitors such as BMS, Merck, Pfizer, and in particular, its Swiss ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, ...

Novartis will also construct four new manufacturing facilities in yet-to-be-announced states – three focused on biologics and one on chemical drug substances. Following the firm’s $1.75bn acquisition ...

Sunshine Biopharma, Inc.'s stock rose over 3% on Monday, lifting retail investor sentiment, after the company said its ...

The draft guidance make the regimen available to HR-positive early-stage breast cancer patients with lymph node-positive disease through the Cancer Drugs Fund.

Investment is expected to bring approximately 1,000 new jobs at Novartis and 4,000 additional roles across the United States.

NVS' first-quarter performance has likely benefited from strong growth in Kisqali, Kesimpta, Pluvicto, Leqvio, Scemblix and ...